Voriconazole in Dermatophytic Infections: An In-depth Examination of Its Role in Tinea Treatment
Abstract
Objective: To evaluate the efficacy of voriconazole in treating dermatophytosis, specifically tinea corporis and tinea cruris, in patients resistant to conventional antifungal treatments. The primary objective was to assess the clinical and mycological cure rates, safety, and potential impact of comorbidities on treatment outcomes. Methodology: A retrospective analysis was conducted at Khyber Teaching Hospital, Peshawar, from June 2021 to June 2022, involving 150 patients with dermatophytosis who had failed previous treatments. Data were collected from medical records, and patients were treated with voriconazole 200 mg twice daily for a duration of 12 weeks. Follow-up visits were conducted at 2, 4, and 12 weeks. Results: The clinical cure rate was 70%, with 50% of patients achieving mycological cure. Male patients showed a higher rate of complete resolution (45%) compared to females (40%), with a p-value of 0.003. Comorbidities such as diabetes and hypertension significantly impacted treatment outcomes, with patients without comorbidities achieving 50% complete resolution, compared to 30% and 35% in diabetic and hypertensive patients, respectively, with a p-value of 0.042. Adverse effects were reported in 25% of patients, including visual disturbances (10%), headaches (8%), and skin rashes (7%). Conclusion: Voriconazole is an effective treatment for dermatophytosis, especially in patients resistant to conventional antifungals. The study highlights the influence of gender and…
Read the paper
Related studies
- The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis
- Updated Perspectives on the Diagnosis and Management of Onychomycosis
- Onychomycosis: Old and New
- Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole
- Terbinafine resistance in Trichophyton mentagrophytes and Trichophyton rubrum in the Czech Republic: A prospective multicentric study
- New drug approvals for 2022: Synthesis and clinical applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.